Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tremeau Pharmceuticals, Inc.
Age
12–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of hemophilia A or B
Either on a stable prophylaxis regimen for their bleeding disorder (factor, bypassing agent, or nonfactor product therapy) OR currently taking or agree to initiate a gastroprotective agent (esomeprazole) for the duration of the trial
Diagnosis of Hemophilic Arthopathy for at least 6 months prior to screening
Chronic symptomatic pain in one or more joint(s) on 20 of the 30 days prior to screening.
Able and willing to wash out of non-study analgesic medications/agents for at least 7 days prior to Randomization including: acetaminophen (paracetamol), NSAIDs, opioids, cannabinoids, topical analgesics, benzodiazepines, gabapentin/pregabalin-containing products and other antiepileptic drugs used for pain
Primary source of pain is due to Hemophilic Arthropathy
You may not be if
Taking opioids for greater than 4 days per week prior to screening
Has a history of advanced renal disease or severe liver disease (within the last 6 months)
Receiving emicizumab while also receiving activated prothrombin complex concentrate (FEIBA)
Uncontrolled or poorly controlled hypertension
History of major cardiac or cerebrovascular disease
History of an upper GI perforation, obstruction, or major GI bleed or current evidence of GI bleeding
Has active hepatitis C or hepatitis B infection or uncontrolled HIV. Note: Patients who are HIV positive are allowed to participate if considered to be controlled.
Has a positive drug screen for all prohibited drugs of potential abuse at screening
Has had an intra-articular injection (within 3 months), initiated physical therapy (within 30 days) or has had orthopedic surgery (within 4 months) prior to screening
Clareo Health | Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy
